SCHEMBL1407508

SCHEMBL1407508

COc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 13/20 0.78
NR1H3 Q13133 13/20 0.78
NR1I2 O75469 2/20 0.56
NR3C1 P04150 2/20 0.56
AR P10275 1/20 0.56
RXRA P19793 1/20 0.56
TP53 P04637 1/20 0.43
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
PTGS1 P23219 2/20 0.42
PTGS2 P35354 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
THPO P40225 1/20 0.42
BLM P54132 1/20 0.42
PMP22 Q01453 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407564 0.92 NR1H2 (0.91) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407336 0.91 NR1H2 (0.80) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407730 0.91 NR1H2 (0.70) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407360 0.90 NR1H2 (0.78) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408390 0.88 NR1H2 (0.75) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407797 0.88 NR1H2 (1.00) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407703 0.88 NR1H2 (1.00) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407553 0.88 NR1H2 (0.86) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407848 0.87 NR1H2 (0.85) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407692 0.86 NR1H2 (0.87) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
CN-101213194-A Indazoles useful in treating cardiovascular diseases WYETH CORP (US) 2008-07-02 CN disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NR1I2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.